Abstracts tagged "randomized trials and systemic lupus erythematosus (SLE)"

Abstract Number: 2643 • 2018 ACR/ARHP Annual Meeting
Sledai-2K Responder Index-50 Is Effective in Demonstrating Partial Response in a Phase 2, Randomized Placebo-Controlled Study of Ustekinumab in Patients with Active Systemic Lupus Erythematosus
Zahi Touma¹, Murray Urowitz², Dafna D Gladman², Carrie Wagner³, Bei Zhou³, Robert Gordon³, Benjamin Hsu³, Marc Chevrier³ and Shawn Rose³, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Krembil Research Institute, U of Toronto, Toronto, ON, Canada, ³Janssen Research & Development, LLC, Spring House, PA
Background/Purpose: Ustekinumab (UST), a monoclonal antibody that targets the shared p40 subunit of the cytokines IL-12 & IL-23, is being investigated in patients (pts) w/…
Abstract Number: 2590 • 2017 ACR/ARHP Annual Meeting
Subcutaneous Belimumab Plus Standard of Care Demonstrated Improvement in Multiple Organ Domains Versus Placebo Plus Standard of Care in Patients with Active Systemic Lupus Erythematosus (SLE)
Andrea Doria¹, Bonnie Pobiner², William Eastman³, Milena Kurtinecz⁴, Anne Hammer², James Groark⁵ and Damon Bass⁵, ¹Division of Rheumatology, University of Padova, Padova, Italy, ²GSK Research Triangle Park, Research Triangle Park, NC, ³GSK, Research Triangle Park, NC, ⁴GSK, Philadelphia, PA, ⁵GSK Collegeville, Collegeville, PA
Background/Purpose : Organ manifestation domain score improvement was assessed with subcutaneous (SC) belimumab (BEL) plus standard SLE care (SoC) in active, autoantibody-positive SLE. Methods: BLISS-SC…
Abstract Number: 12L • 2016 ACR/ARHP Annual Meeting
Efficacy and Safety of Atacicept in Patients with Systemic Lupus Erythematosus: Results of a 24-Week Randomized, Placebo-Controlled, Phase IIb Study
Joan T. Merrill¹, Daniel J. Wallace², Stephen Wax³, Amy Kao⁴, Patricia Fraser⁴, Wai Chin⁴ and David A. Isenberg⁵, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of California Los Angeles, Los Angeles, CA, ³EMD Serono, BIllerica, MA, ⁴EMD Serono, Billerica, MA, ⁵University College Hospital, London, London, United Kingdom

Background/Purpose: Atacicept targets B-cell stimulating factors BLyS and APRIL. In the APRIL-SLE trial, atacicept 150 mg was associated with reduced SLE flares in post-hoc analyses.1Methods:…
Abstract Number: 1809 • 2015 ACR/ARHP Annual Meeting
Real Life Implementation of Lupus Nephritis Randomized Controlled Trials
Angela Pakozdi¹, Ravindra Rajakariar², Muhammad Magdi Yaqoob² and Dev Pyne¹, ¹Rheumatology, Barts Health NHS Trust, London, United Kingdom, ²Renal Medicine, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Randomized controlled trials (RCTs) are the gold standard for assessing treatment efficacy. However, due to their often strict design, generalization of research results to…
Abstract Number: 2688 • 2012 ACR/ARHP Annual Meeting
The Health Improvement and Prevention Program in Systemic Lupus Erythematosus Demonstrates Improvement in Mental Health and Framingham Risk Score At One Year
Paul R. Fortin¹, Ellie Aghdassi², Anne Cymet³, Stacey Morrison⁴, Willy Wynant⁵, Janet E. Pope⁶, Sara Hewitt⁷, Christian A. Pineau⁸, Carolyn Neville⁹, Paula Harvey¹⁰, Jean-Claude Tardif¹¹, Michal Abrahamowicz¹² and Deborah DaCosta¹³, ¹Medicine, Centre de Recherche du Chu de Québec et Université Laval, Quebec City, QC, Canada, ²University Health Network Research Institute - Western Division, Toronto, ON, Canada, ³Nursing, University Health Network - Western Division, Toronto, ON, Canada, ⁴Div Rheumatology Rm MP-10-304, The Toronto Western Hospital, Toronto, ON, Canada, ⁵Division of Clinical Epidemiology, McGill University Health Centre and McGill University, Montreal, QC, Canada, ⁶Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁷Rheumatology, St. Joseph's Health Care, University of Western Ontario, London, ON, Canada, ⁸Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁹Epidemiology, Royal Victoria Hospital, Montreal, QC, Canada, ¹⁰Cardiology, Women's College Hospital, Toronto, ON, Canada, ¹¹Montreal Heart Institute, Universite de Montreal endowed research chair in atherosclerosis, Quebec, QC, Canada, ¹²Clinical Epidemiology, McGill University, Montreal, QC, Canada, ¹³Montreal General Hospital, Montreal, Canada
Background/Purpose: The Health Improvement and Prevention Program (HIPP) is a behavioral intervention aimed at improving health status and coping of persons with lupus while reducing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].